MediciNova
MediciNova, Inc. is a biopharmaceutical company based in La Jolla, California, that specializes in acquiring and developing novel small-molecule therapeutics aimed at addressing serious diseases with unmet medical needs in the United States. The company's product pipeline features several clinical-stage compounds, including MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent intended for neurological disorders such as multiple sclerosis and amyotrophic lateral sclerosis. Other notable products include MN-221, which targets acute exacerbations of asthma, and MN-001, a treatment for fibrotic diseases like nonalcoholic steatohepatitis. MediciNova is also engaged in the development of therapies for various conditions, including substance dependence and solid tumor cancers. The company collaborates with Japanese pharmaceutical firms and has a partnership for the joint development of a SARS-CoV-2 vaccine. Founded in 2000, MediciNova is committed to advancing therapeutics that offer significant commercial potential and address critical health challenges.
Avigen, Inc., a biopharmaceutical company, engages in identifying and developing products to treat patients with neurological and other disorders. The company develops the AV411 portfolio, which includes the phase II-stage lead drug compound and proprietary analogs and represents novel, non-opioid drugs for the treatment of various large pain and drug addiction indications. AV411 is an orally bioavailable small molecule; a glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6; and a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. AV411 is being evaluated in Phase Ib/IIa clinical trials. The company was founded in 1992 and is headquartered in Alameda, California. As of December 18, 2009, Avigen, Inc. operates as a subsidiary of MediciNova Inc
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.